Gilead: Second trial of 4-drug AIDS pill meets goal (Reuters)
Reuters – Gilead Sciences Inc’s four-drug experimental HIV pill worked as well as a regimen containing protease inhibitor Reyataz in the second pivotal trial of the drug, the company said on Monday.